Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|October 25, 2024

Emerging Trends and Rising Prevalence of mCSPC

Author(s)Joeseph Renzulli, MD, Ganesh V. Raj, MD, PhD, Scott B. Sellinger, MD

Key Takeaways

Improved diagnostic techniques and an aging population contribute to the increasing prevalence of mCSPC.
Earlier detection and personalized therapeutic strategies are becoming more common in mCSPC management.
Advances in imaging and biomarker identification enhance disease characterization and treatment precision.
Understanding molecular and genetic aspects of mCSPC is crucial for developing novel targeted therapies.

SHOW MORE

Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.

Episodes in this series

EP. 1 Emerging Trends and Rising Prevalence of mCSPC

EP. 1 Emerging Trends and Rising Prevalence of mCSPC

EP. 2 Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

EP. 2 Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification

EP. 3 Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

EP. 3 Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches

EP. 4 Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

EP. 4 Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions

EP. 5 Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

EP. 5 Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial

EP. 6 Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

EP. 6 Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

EP. 7 Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy

EP. 7 Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy

Video content above is prompted by the following:

What is the prevalence of mCSPC? What trends have emerged in recent years?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves first-line Zenflow system for the treatment of BPH

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

© 2025 MJH Life Sciences^®

All rights reserved.